NOVATO, CA / ACCESSWIRE / December 30, 2020 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:PTSCD), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that The Financial Industry Regulatory Authority, Inc., (FINRA), has approved a change in the Company's stock symbol trading on the OTC Markets Pink. Beginning on December 31, 2020, Mosaic's trading symbol will change to "CPMV" on the OTC Markets Pink. The new trading symbol, CPMV, is derived from CowPea Mosaic Virus, which is central to the Company's core technology platform. Previously, the Company's common stock was quoted on the OTC Markets Pink tier under the trading symbol "PTSCD." The Company's corporate website is located at www.mosaicie.com.

"This symbol change aligns with our company's primary focus to advance the development of our novel immuno-oncology platform to treat and prevent a wide range of cancers," stated Steven King, president and chief executive officer of Mosaic. "Based on broad and consistent preclinical data, our lead therapeutic candidate, MI-O-101, derived from cowpea mosaic virus, appears well positioned in the promising area of immunotherapy agents that stimulate immune cells to recognize and fight cancer. We look forward to updating our stockholders regarding upcoming publications, presentations and our discussions with regulatory agencies    https://finance.yahoo.com/news/mosaic-immunoengineering-inc-announces-stock-221000321.html